Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
27 10 2021
Historique:
received: 09 07 2021
accepted: 08 10 2021
entrez: 28 10 2021
pubmed: 29 10 2021
medline: 27 1 2022
Statut: epublish

Résumé

Haematopoietic malignancies are frequently characterized by karyotypic abnormalities. The development of targeted drugs has been pioneered with compounds against gene products of fusion genes caused by chromosomal translocations. While polysomies are equally frequent as translocations, for many of them we are lacking therapeutic approaches aimed at synthetic lethality. Here, we report two new cell lines, named MBU-7 and MBU-8, that differ in complete trisomy of chromosome18, a partial trisomy of chromosome 7 and a tetrasomy of the p-arm of chromosome 8, but otherwise share the same mutational pattern and complex karyotype. Both cell lines are divergent clones of U-937 cells and have the morphology and immunoprofile of monocytic cells. The distinct karyotypic differences between MBU-7 and MBU-8 are associated with a difference in the specific response to nucleoside analogues. Taken together, we propose the MBU-7 and MBU-8 cell lines described here as suitable in vitro models for screening and testing vulnerabilities that are associated with the disease-relevant polysomies of chromosome 7, 8 and 18.

Identifiants

pubmed: 34707142
doi: 10.1038/s41598-021-00623-w
pii: 10.1038/s41598-021-00623-w
pmc: PMC8551338
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21145

Subventions

Organisme : Marie Curie
ID : H2020-MSCA-ITN-2015-675610
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Cancer Discov. 2014 Mar;4(3):362-75
pubmed: 24346116
Blood. 2010 Nov 18;116(20):4086-94
pubmed: 20693432
Nat Rev Drug Discov. 2020 Jan;19(1):23-38
pubmed: 31712683
J Biomol Tech. 2018 Jul;29(2):25-38
pubmed: 29805321
Cancer Genet Cytogenet. 2005 Aug;161(1):78-81
pubmed: 16080962
Leuk Lymphoma. 2018 Feb;59(2):274-287
pubmed: 28573892
Curr Treat Options Oncol. 2019 Feb 11;20(2):15
pubmed: 30741367
Cytometry B Clin Cytom. 2021 May;100(3):292-295
pubmed: 32830878
Leukemia. 2015 Jun;29(6):1290-300
pubmed: 25650089
Cancers (Basel). 2021 Apr 06;13(7):
pubmed: 33917538
Genet Med. 2016 Feb;18(2):128-36
pubmed: 25880439
Leukemia. 1997 Dec;11(12):2032-8
pubmed: 9447816
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
Leuk Lymphoma. 2004 Apr;45(4):639-48
pubmed: 15160934
Hemasphere. 2020 Sep 01;4(5):e466
pubmed: 33062944
Leukemia. 2017 Oct;31(10):2271-2273
pubmed: 28751768
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4804-9
pubmed: 8643484
DNA Repair (Amst). 2006 Sep 8;5(9-10):1282-97
pubmed: 16893685
FASEB J. 2005 Mar;19(3):434-6
pubmed: 15637111
Cytotechnology. 1992;8(1):13-20
pubmed: 1369387
Nature. 1994 Nov 10;372(6502):143-9
pubmed: 7969446
Blood. 1992 May 1;79(9):2378-83
pubmed: 1571549
Nature. 2010 Dec 23;468(7327):1105-9
pubmed: 21179167
Cancer Genet Cytogenet. 2002 Sep;137(2):124-32
pubmed: 12393283
Mol Cytogenet. 2020 Dec 14;13(1):50
pubmed: 33317567
PLoS One. 2011;6(8):e23372
pubmed: 21858090
Clin Epigenetics. 2016 Jun 21;8:71
pubmed: 27330573
Blood. 2018 Mar 29;131(13):1406-1414
pubmed: 29438960
Expert Rev Hematol. 2019 Nov;12(11):947-958
pubmed: 31422708
N Engl J Med. 2006 Oct 5;355(14):1456-65
pubmed: 17021321
Blood. 2000 Dec 1;96(12):3932-8
pubmed: 11090080
J Leukoc Biol. 1985 Apr;37(4):407-22
pubmed: 3855947
Int J Cancer. 1976 May 15;17(5):565-77
pubmed: 178611
Pathol Biol (Paris). 2007 Feb;55(1):37-48
pubmed: 16697122
Blood Rev. 2004 Jun;18(2):115-36
pubmed: 15010150
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Cytogenet Cell Genet. 2001;94(1-2):9-14
pubmed: 11701946
Int J Cancer. 2016 Sep 1;139(5):1106-16
pubmed: 27074337
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):328-339
pubmed: 29340131
J Mol Diagn. 2013 Mar;15(2):186-95
pubmed: 23318495
Blood. 2011 Oct 6;118(14):3803-10
pubmed: 21828143
Exp Hematol. 1997 Apr;25(4):312-20
pubmed: 9131006
Genes Chromosomes Cancer. 2017 Mar;56(3):243-252
pubmed: 27750403
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Leukemia. 2008 Nov;22(11):2029-40
pubmed: 18685615
Biotechniques. 1993 Jul;15(1):100-19
pubmed: 8103347
Blood. 2012 Jun 14;119(24):5824-31
pubmed: 22490330
Expert Rev Anticancer Ther. 2003 Oct;3(5):717-28
pubmed: 14599094

Auteurs

Michael Maher (M)

Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Jeannine Diesch (J)

Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, 08916, Badalona, Spain.

Marguerite-Marie Le Pannérer (MM)

Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Marta Cabezón (M)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Mar Mallo (M)

Microarrays Unit, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
MDS Group, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Sara Vergara (S)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Aleix Méndez López (A)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Alba Mesa Tudel (A)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Francesc Solé (F)

Microarrays Unit, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.
MDS Group, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Marc Sorigue (M)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Lurdes Zamora (L)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Isabel Granada (I)

Department of Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain.

Marcus Buschbeck (M)

Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute (IJC), 08916, Badalona, Spain. mbuschbeck@carrerasresearch.org.
Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, 08916, Badalona, Spain. mbuschbeck@carrerasresearch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH